Ketamine modulates theta and gamma oscillations.

Neuroengineering Laboratory, Department of Bioengineering, University of Pennsylvania, Philadelphia 19104, USA.
Journal of Cognitive Neuroscience (Impact Factor: 4.69). 08/2009; 22(7):1452-64. DOI: 10.1162/jocn.2009.21305
Source: PubMed

ABSTRACT Ketamine, an N-methyl-D-aspartate (NMDA) receptor glutamatergic antagonist, has been studied as a model of schizophrenia when applied in subanesthetic doses. In EEG studies, ketamine affects sensory gating and alters the oscillatory characteristics of neuronal signals in a complex manner. We investigated the effects of ketamine on in vivo recordings from the CA3 region of mouse hippocampus referenced to the ipsilateral frontal sinus using a paired-click auditory gating paradigm. One issue of particular interest was elucidating the effect of ketamine on background network activity, poststimulus evoked and induced activity. We find that ketamine attenuates the theta frequency band in both background activity and in poststimulus evoked activity. Ketamine also disrupts a late, poststimulus theta power reduction seen in control recordings. In the gamma frequency range, ketamine enhances both background and evoked power, but decreases relative induced power. These findings support a role for NMDA receptors in mediating the balance between theta and gamma responses to sensory stimuli, with possible implications for dysfunction in schizophrenia.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Reductions in glutamate function are regarded as an important contributory factor in schizophrenia. However, there is a paucity of animal models characterized by developmental and sustained reductions in glutamate function. Pharmacological models using NMDA antagonists have been widely used but these typically produce only transient changes in behavior and brain function. Likewise, mice with homozygous constitutive reductions in glutamate receptor expression show stable brain and behavioral changes, but many of these phenotypes are more severe than the human disease. The current study examines a variety of schizophrenia-related EEG measures in mice with a heterozygous alteration of the NMDA receptor NR1 subunit gene (NR1) that is known to result in reduced NR1 receptor expression in the homozygous mouse (NR1−/−). (NR1+/−) mice showed a 30% reduction in NR1 receptor expression and were reared after weaning in either group or isolated conditions. Outcome measures include the response to paired white noise stimuli, escalating inter-stimulus intervals (ISIs) and deviance-related mismatch negativity (MMN). In contrast to what has been reported in (NR1−/−) mice and mice treated with NMDA antagonists, (NR1+/−) mice showed no change on obligatory Event Related Potential (ERP) measures including the murine P50 and N100 equivalents (P20 and N40), or measures of baseline or evoked gamma power. Alternatively, (NR1+/−) mice showed a marked reduction in response to a deviant auditory tone during MMN task. Data suggest that EEG response to deviant, rather than static, stimuli may be more sensitive for detecting subtle changes in glutamate function. Deficits in these heterozygous NR1 knockdown mice are consistent with data demonstrating MMN deficits among family members of schizophrenia patients and among prodromal patients. Therefore, the current study suggests that (NR1+/−) mice may be among the most sensitive models for increased vulnerability to schizophrenia.
    Neurobiology of Disease 01/2015; 73. DOI:10.1016/j.nbd.2014.10.010 · 5.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Impairments in spatial and temporal integration of brain network activity are a core feature of schizophrenia. Neural network oscillatory activity is considered to be fundamentally important in coordinating neural activity throughout the brain. Hence, exploration of brain oscillations has become an indispensible tool to study the neural basis of mental illnesses. However, most of the studies in schizophrenia include medicated patients. This implicates the question to what extent are changes in the electrophysiological parameters genuine illness effects, genuine drug effects or a mixture of both. We here provide a short overview of the neuropharmacology of brain oscillations with respect to schizophrenia.
    International Journal of Psychophysiology 02/2015; DOI:10.1016/j.ijpsycho.2015.02.014 · 2.65 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: As a complex neuropsychiatric disease with both hereditary and environmental components, schizophrenia must be understood across multiple biological scales, from genes through cells and circuits to behaviors. The key to evaluating candidate explanatory models, therefore, is to establish causal links between disease-related phenomena observed across these scales. To this end, there has been a resurgence of interest in the circuit-level pathophysiology of schizophrenia, which has the potential to link molecular and cellular data from risk factor and post-mortem studies with the behavioral phenomena that plague patients. The demonstration that patients with schizophrenia frequently have deficits in neuronal synchrony, including deficits in local oscillations and long-range functional connectivity, offers a promising opportunity to forge such links across scales.
    Current Opinion in Neurobiology 09/2014; 30C:17-23. DOI:10.1016/j.conb.2014.08.009 · 6.77 Impact Factor

Full-text (2 Sources)

Available from
May 29, 2014

Maciej Lazarewicz